Haemonetics amends agreement with Arryx for expanded field of use

By Jennifer Chiou

New York, Oct. 27 - Haemonetics Corp. and Arryx, Inc. announced an amended agreement that expands Haemonetics' rights to use Arryx's optical trapping technology to develop applications in a broader field of use.

Haemonetics will make a one-time payment to Arryx of $3 million and will also make milestone payments of up to $12.4 million when Arryx reaches proof of concept, development and regulatory deliverables on future projects.

Other terms of the amended agreement were not disclosed.

In October 2004, Haemonetics and Arryx had announced a collaboration to develop new technology for applications in a narrower field of use for blood processing.

Based in Braintree, Mass., Haemonetics designs and manufactures automated blood processing systems.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.